Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 2:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 3,045 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Long Term Clear all
Recruiting Not applicable Interventional

A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship

NCT07013435
View directory record Official record
Conditions
Lymphoma
Interventions
Health Education Program, SMART3RP-Lymphoma
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 16, 2026, 2:25 AM EDT
Completed Phase 1Phase 2 Interventional

Long-Term Exercise Maintenance Via Internet Support

NCT00260117
View directory record Official record
Conditions
Obesity, Inactivity
Interventions
Exercise
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
16,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2010 · Synced Oct 16, 2026, 2:25 AM EDT
Not listed No phase listed Observational

A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501

NCT04080050
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia (HoFH)
Interventions
Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy
Drug
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
4
States / cities
Columbus, Ohio • Portland, Oregon • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Oct 16, 2026, 2:25 AM EDT
Completed Not applicable Interventional

Promoting Seniors' Health With Home Care Aides

NCT03301116
View directory record Official record
Conditions
Muscle Weakness
Interventions
Healthy Moves for Aging Well (Healthy Moves), Active Mind for Aging Well (Active Mind)
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
60 Years to 110 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 16, 2026, 2:25 AM EDT
Recruiting Not applicable Interventional

Liver Transplantation From Donors With HIV: Impact on Opportunistic Infections, Cancer, and Long-Term Outcomes (Expanding HOPE Liver)

NCT07665372
View directory record Official record
Conditions
HIV
Interventions
HIV D-/R+
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
19
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 16, 2026, 2:25 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

NCT04596995
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Rozanolixizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 16, 2026, 2:25 AM EDT
Enrolling by invitation Phase 2 Interventional

Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells

NCT03628612
View directory record Official record
Conditions
Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric, T Cell Lymphoma
Interventions
AUTO CAR T cell therapy
Biological
Lead sponsor
Autolus Limited
Industry
Eligibility
1 Year and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2043
U.S. locations
3
States / cities
Miami, Florida • St Louis, Missouri • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 16, 2026, 2:25 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

NCT00622700
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
19
States / cities
Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 16, 2026, 2:25 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

NCT04777201
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Faricimab, Sham Procedure, Anti-VEGF Therapy
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
1,036 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
85
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 16, 2026, 2:25 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

NCT06164951
View directory record Official record
Conditions
Achondroplasia
Interventions
Infigratinib 0.25 mg/kg/day, Placebo Comparator 0.25 mg/kg/day
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
3 Years to 17 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 16, 2026, 2:25 AM EDT
Completed No phase listed Observational

Retrospective Database Review at LTC and SNFs

NCT06068972
View directory record Official record
Conditions
Non-Healing Ulcer of Skin, Autofluorescence Imaging
Interventions
MolecuLight
Device
Lead sponsor
Wound Care Plus, LLC
Industry
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Blue Springs, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 16, 2026, 2:25 AM EDT
Active, not recruiting Phase 1 Interventional

A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration

NCT01678872
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
RetinoStat
Drug
Lead sponsor
Oxford BioMedica
Industry
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2029
U.S. locations
3
States / cities
Iowa City, Iowa • Baltimore, Maryland • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 16, 2026, 2:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study to Investigate Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Pain Derived From Exposed Dentine in Response to Chemical, Thermal, Tactile, or Osmotic Stimuli.

NCT02651467
View directory record Official record
Conditions
Dentin Sensitivity
Interventions
Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0), Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5), Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 16, 2026, 2:25 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Clinical Time and Temporal Dynamics Study (CLIN-TIME)

NCT07812831
View directory record Official record
Conditions
Longitudinal Studies, Prospective Studies, Biomarkers, Predictive Value of Tests, Telemedicine, Time of Death, Time Perception, Time Reaction, Time Efficiency, Time Management, Population, Population Groups, Epidemic Disease, Pandemic, Sex Behavior, Sex Characteristics, Sex Hormone, Cardio-pulmonary, Surgical, Drugs of Abuse, Health Risks, Clinical Outcomes
Interventions
No Study-Assigned Intervention
Other
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2076
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 16, 2026, 2:25 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

NCT01931839
View directory record Official record
Conditions
Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Interventions
Lumacaftor Plus Ivacaftor Combination, Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
1,164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
91
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 16, 2026, 2:25 AM EDT
Terminated No phase listed Observational

Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants

NCT04506619
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP), Intraventricular Hemorrhage, Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity
Interventions
No Intervention
Other
Lead sponsor
Oak Hill Bio Ltd
Industry
Eligibility
12 Months to 24 Months
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
South Bend, Indiana • Jackson, Mississippi • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 16, 2026, 2:25 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Outcomes AlloMap Registry: the Long-term Management and Outcomes of Heart Transplant Recipients With AlloMap Testing

NCT01833195
View directory record Official record
Conditions
Cardiac Transplant Failure, Cardiac Transplant Rejection, Heart Diseases
Interventions
Not listed
Lead sponsor
CareDx
Industry
Eligibility
15 Years and older
Enrollment
2,444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
36
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 16, 2026, 2:25 AM EDT
Completed Phase 2 Interventional Results available

CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy

NCT02654977
View directory record Official record
Conditions
Familial Partial Lipodystrophy, Nonalcoholic Steatohepatitis, NAFLD
Interventions
Metreleptin
Drug
Lead sponsor
University of Michigan
Other
Eligibility
5 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 16, 2026, 2:25 AM EDT
Active, not recruiting No phase listed Observational

Long-Term Follow-up Study for Patients From AVXS-101-CL-101

NCT03421977
View directory record Official record
Conditions
Spinal Muscular Atrophy 1
Interventions
Onasemnogene Abeparvovec-xioi
Biological
Lead sponsor
Novartis Gene Therapies
Industry
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 16, 2026, 2:25 AM EDT
Recruiting No phase listed Observational

Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device

NCT07389473
View directory record Official record
Conditions
ADHD, Depression Disorders, Mood Disorders, Anxiety Disorder Generalized, Bipolar Disorder (BPD)
Interventions
Prescription Psychotropic Medications
Drug
Lead sponsor
Gaize
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 16, 2026, 2:25 AM EDT
Completed Phase 4 Interventional

A Study to Explore if Long-term Use of Mucinex Can Help With Symptoms in Patients With Stable Chronic Bronchitis.

NCT05843669
View directory record Official record
Conditions
Chronic Bronchitis
Interventions
Guafenesin tablets
Drug
Lead sponsor
American Health Research
Other
Eligibility
40 Years to 90 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Charlotte, North Carolina • Rock Hill, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 16, 2026, 2:25 AM EDT
Completed Phase 3 Interventional

A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression

NCT00250653
View directory record Official record
Conditions
Depressive Disorder
Interventions
Saredutant succinate (SR48968C)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 16, 2026, 2:25 AM EDT
Terminated Phase 3 Interventional Results available

A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

NCT03556202
View directory record Official record
Conditions
Psoriasis
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,936 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
47
States / cities
Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 16, 2026, 2:25 AM EDT
Completed No phase listed Observational

Long-term Outcomes and Life Satisfaction of Adults With Pediatric-Onset Spinal Cord Injuries

NCT00876837
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Not listed
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
19 Years to 100 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Oct 16, 2026, 2:25 AM EDT